Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma.
The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure brings Optune tech to drug trial for glioblastoma appeared first on MassDevice.